5-MBPB (also known as 5-MPBP and 5-MABB) is an amphetamine and phenylisobutylamine derivative which is structurally related to MDMA and has been sold as a designer drug. It can be described as the benzofuran-5-yl analogue of MBDB or the butanamine homologue of 5-MAPB, and is also a structural isomer of 5-EAPB and 6-EAPB. Anecdotal reports suggest this compound has been sold as a designer drug in various European countries since early 2015, but the first definitive identification was made in December 2015 by a forensic laboratory in Slovenia.European Monitoring Center for Drugs and Drug Addiction – Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA
5-MBPB is similar in structure to compounds such as 5-APB which are claimed to be agonists of the 5-HT2C receptor.
5-MBPB (5-MABB) has been found to act as a potent serotonin–norepinephrine–dopamine releasing agent (SNDRA), with preference for induction of serotonin release over norepinephrine and dopamine release, and fully substitutes for MDMA in animal drug discrimination tests. Unlike 5-MAPB, it is a relatively weak serotonin 5-HT1B receptor agonist.
See also Substituted benzofuran 6-MBPB (6-MABB)
References
External links 5-MBPB (5-MABB) - Isomer Design